Compare ResMed Inc. (RMD) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Boston Beer Company Inc — how do they compare? ResMed Inc. trades at $199.01 (market cap $28.81B), while Boston Beer Company Inc trades at $171.7 (market cap $1.88B). The key difference: ResMed Inc. is far larger — about 15.3× Boston Beer Company Inc's market cap, and ResMed Inc. pays a 1.21% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| RMD | SAM | |
|---|---|---|
Market Cap | $28.81B | $1.88B |
Sector | Health | Consumer Staples |
52-Week High | $293.73 | $260.05 |
52-Week Low | $182.82 | $161.08 |
Enterprise Value | $27.99B | $1.75B |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Boston Beer Company (SAM) trades at $180.59, up 1.0% with a bullish technical signal from moving averages. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.99, but negative net income margin and ROE. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Analyst consensus is mixed with 74% hold ratings and a $204.33 price target, suggesting modest upside potential from current levels.
SAM faces near-term challenges including volume declines and competitive pressures in the hard seltzer segment, offset by strong cash flow generation and innovation in Beyond Beer categories. The company's improved gross margins and cost-saving initiatives provide some stability, but investor sentiment remains cautious ahead of Q2 earnings. The stock presents a balanced risk-reward profile with potential upside to analyst targets but requires monitoring of execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
